- Stoller trae ventas globales de +$400 millones y presencia en más de 60 países
- Refuerza el compromiso de generar valor para los agricultores a través de soluciones innovadoras y sostenibles
- Segunda transacción de productos biológicos de Corteva desde la finalización de las revisiones estratégicas de la cartera
INDIANAPOLIS y HOUSTON, 30 de noviembre de 2022 — Corteva, Inc. (NYSE: CTVA) y Stoller Group, Inc. ("Stoller") anunciaron hoy que Corteva ha firmado un acuerdo definitivo para adquirir Stoller, con sede en Houston, una de las mayores Empresa de productos biológicos en la industria. Con operaciones y ventas en más de 60 países e ingresos previstos para 2022 de más de 400 millones de dólares, Stoller aporta escala y rentabilidad inmediatas, con márgenes de EBITDA que beneficiarán a Corteva.
La adquisición de Stoller refuerza el compromiso de Corteva de proporcionar a los agricultores herramientas biológicas que complementen las prácticas agrícolas en evolución y les ayuden a cumplir con las expectativas cambiantes del mercado. La reputación superior de Stoller en cuanto a las relaciones con los agricultores y la creación de demanda se centra en un modelo comercial que se basa en compartir conocimientos con el canal y los agricultores. Stoller ha tenido éxito demostrando excelencia técnica y brindando beneficios y valor de soluciones integradas en el campo.
“Los productos biológicos brindan a los agricultores herramientas con ventajas sostenibles que complementan las tecnologías de protección de cultivos y, en conjunto, pueden trabajar para abordar los desafíos globales relacionados con la seguridad alimentaria y el cambio climático. Stoller representa un líder en la industria de productos biológicos dada su presencia comercial y potencial de expansión de mercado, al tiempo que ofrece un crecimiento y márgenes operativos atractivos”, dijo Chuck Magro, director ejecutivo.
“In combination with Corteva’s leading innovation organization, Stoller provides a platform for expanding and accelerating Corteva’s Biologicals business to become one of the largest players in the rapidly expanding Biologicals market.”
Se espera que el mercado de productos biológicos crezca un dígito alto anualmente hasta 2035, lo que representa aproximadamente el 25 % del mercado general de protección de cultivos para 2035. En solo tres años, Corteva ha desarrollado un negocio de productos biológicos de clase mundial mediante la implementación de estrategias inteligentes y ágiles basadas en e innovación interna, colaboraciones de I+D, acuerdos de licencia y distribución y adquisiciones.
“En los más de 50 años de historia de Stoller, hemos ayudado con éxito a los productores de todo el mundo a aumentar su productividad y mejorar su sostenibilidad. Estamos orgullosos de unir fuerzas con Corteva mientras compartimos la visión de ayudar a los agricultores a tener éxito en el cultivo de los alimentos nutritivos de los que depende el mundo”, dijo Guillermo de la Borda, director ejecutivo de Stoller.lly hasta 2035, que representa aproximadamente el 25 % del total. mercado de protección de cultivos para 2035. En solo tres años, Corteva ha desarrollado un negocio de productos biológicos de clase mundial mediante la implementación de estrategias inteligentes y ágiles construidas en torno a la innovación interna y externa, colaboraciones de I+D, licencias y acuerdos de distribución y adquisiciones.
“This announcement is a true testament to the incredible success and dedication of our teams across the globe who have helped us become one of the most trusted biostimulant and plant health companies in the world. Our innovative solutions and deep expertise will continue to make an impact for years to come.”
Stoller is the second Biologicals acquisition for Corteva this year, as the company recently announced it signed a definitive agreement to acquire Symborg, an expert in microbiological technologies based in Murcia, Spain. Corteva will bring together the complementary commercial and technical strengths of Stoller and Symborg as part of its Biologicals strategy.
The Stoller purchase price of $1.2 billion in cash represents an enterprise value multiple of approximately 12x based on Stoller’s expected EBITDA for 2022 on a stand-alone basis. The purchase price will be paid at closing, which is anticipated to be completed in the first half of 2023 following regulatory approvals and satisfaction of customary closing conditions. The Company expects that Stoller results will be accretive to both Operating EBITDA and Operating EPS for 2023.
The Company will host a live webcast on Monday, Dec. 5, from 11:00 a.m. to 11:30 a.m. EST to discuss additional details regarding the transaction and the Company’s overall Biologicals strategy.
This presentation will be webcast. Registration is available on the Events and Presentations Page of the Corteva Investor Relations website. A replay will also be available on the Investor Events and Presentations page until Dec. 5, 2023.
Evercore is serving as the financial advisor to Corteva. J.P. Morgan Securities LLC is serving as lead financial advisor and Piper Sandler is serving as financial advisor to Stoller Group. Latham & Watkins served as legal advisor to Stoller.
Stoller is a multinational plant-science company whose vision is to deliver solutions that empower customers’ sustainability. Stoller helps growers around the world succeed with science-proven offerings that include physiological-signaling compounds, such as plant hormones, high-technology nutrients, and microorganisms that can be used alone or in combination to improve plant efficiency and promote plant resilience to stress. For more than 50 years, Stoller has blended its innovative, quality solutions with its deep-rooted knowledge in plant physiology, so plants can maximize their genetic potential, increasing yield and profit for progressive growers. For more information, visit stolleragro.com.
# # #
Cautionary Statement About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “targets,” “estimates,” “outlook,” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about completion of this transaction and Corteva’s financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; environmental, social and governance (“ESG”) targets and initiatives; and the anticipated benefits of acquisitions restructuring actions, or cost savings initiatives are forward-looking statements.
Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva’s business, results of operations and financial condition. With respect to the contemplated transactions, forward-looking statements include, without limitation, financial estimates, statements as to the completion and benefits or effects of the transactions, including financial and operating results, the combined company’s plans, objectives, expectations and intentions, and other statements that are not historical facts. The following risks, uncertainties and other factors could affect the company’s financial performance and cause actual results to differ materially from those expressed or implied in any forward-looking statements: the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive agreement for these transactions; the risk that the necessary regulatory approvals may not be obtained as a result of conditions that are not anticipated; risks that any of the closing conditions to the transaction[s] may not be satisfied in a timely manner; the failure to realize the benefits of the transactions or Corteva’s biologicals strategy; the effect of the announcement of the transactions on the ability of Symborg and Stoller to retain customers and key personnel and to maintain relationships with suppliers, and on their operating results and business generally; and potential litigation in connection with the transactions.
Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the “Risk Factors” section of Corteva’s Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.
Media Relations Contact:
Investor Relations Contact: